2021 National Immunization Survey Results
Immunization Coverage Among Texas Teens 13-17 Years Old - 2021
Source: CDC NIS-Teen Report
About the National Immunization Survey-Teen (NIS-Teen)
The NIS-Teen is a national survey conducted every year by the Centers for Disease Control and Prevention (CDC) to assess vaccination coverage levels, or the percentage of people vaccinated, among adolescents 13-17 years of age. This study collects data by interviewing households in all 50 states, the District of Columbia, and smaller selected areas. The interviews are conducted by telephone, with households selected at random. To ensure the accuracy of vaccination coverage estimates, participant vaccination records are collected from healthcare providers by mail after the interview. The parents and guardians of eligible teens are asked during the telephone interview for consent to contact the adolescents’ vaccination providers to verify their records.
The NIS-Teen was established to provide an ongoing and consistent data set for analyzing vaccination coverage levels among adolescents in the United States and to share this information with interested public health partners. The NIS-Teen provides national and statewide estimates of vaccination coverage, including new vaccines as they are licensed and recommended for use. It also helps track progress towards the Healthy People 2030 goals.
Survey Sample
The survey assessed the vaccination histories of approximately 18,000 U.S. adolescents aged 13-17 years between January 2021 and February 2022. These adolescents were born between January 2003 and February 2009. A total of 990 Texas teens were interviewed as part of this study, with estimated vaccination coverage levels for the state of Texas and two local Texas areas – the City of Houston and Bexar County.
Vaccines Included
The following vaccine doses routinely recommended for adolescents starting at 11-12 years of age, were measured in the 2021 NIS-Teen:
- ≥1 dose of Tetanus-diphtheria-pertussis (Tdap) vaccine
- ≥1 dose of Quadrivalent Meningococcal Conjugate (MenACWY) vaccine
- ≥1 dose of human papillomavirus (HPV) vaccine
- HPV vaccine, Up-to-Date, either two or three doses dependent on age of initiation
The NIS-Teen also measures coverage for the following catch-up schedule vaccines, for teens who did not complete them as recommended when they were younger:
- ≥2 doses measles, mumps, and rubella (MMR) vaccine.
- ≥2 doses varicella (VAR) vaccine.
- ≥2 doses hepatitis A (HepA) vaccine.
Vaccination Coverage Levels
|
Vaccine |
U.S. 2021 |
Texas 2020 |
Texas 2021 |
Texas Percentage |
|---|---|---|---|---|
|
≥1 dose of tetanus-diphtheria-acellular pertussis (Tdap) |
89.6% |
84.0% |
87.1% |
3.1% |
|
≥1 dose of meningococcal conjugate (MenACWY) |
89.0% |
91.2% |
90.0% |
-1.2% |
|
≥1 dose of human |
76.9% |
72.8% |
71.3% |
-1.5% |
|
HPV Up-To-Date (HPV UTD) |
61.7% |
54.9% |
51.5%c |
-3.4% |
|
≥1 dose of HPV, females |
78.5% |
76.1% |
73.4% |
-2.7% |
|
HPV UTD, females |
63.8% |
57.0% |
54.8% |
-2.2% |
|
≥1 of HPV, males |
75.4% |
69.6% |
69.2% |
-0.4% |
|
HPV UTD, males |
59.8% |
52.9% |
48.3%c |
-4.6% |
|
≥2 doses of measles, mumps, |
92.2% |
85.9% |
84.1%c |
-1.8% |
|
≥2 doses of varicella (VAR) |
91.5% |
86.7% |
84.7%c |
-2.0% |
|
≥2 HepA |
85.0% |
87.1% |
84.3% |
-2.8% |
a Significantly greater (p<.0.05) than the U.S. estimate
b Statistically significant difference (p<0.05) between years
c Significantly lower (p<0.05) than the U.S. estimate
View accessible data table of chart below:
NIS-Teen Immunization Coverage Estimates for Tdap and MenACWY by Jurisdiction, 2021
|
Vaccine |
U.S. |
Texas |
City of Houston |
Bexar County |
|
|---|---|---|---|---|---|
|
≥1 Tdap |
89.6% |
87.1% |
86.0% |
84.3% |
|
|
≥1 MenACWY |
89.0% |
90.0% |
93.1% |
90.5% |
|
View accessible data table of chart below:
NIS-Teen Immunization Coverage Estimates for HPV by Gender and Jurisdiction, 2021
| Vaccine | U.S. | Texas | City of Houston | Bexar County | ||||
|---|---|---|---|---|---|---|---|---|
|
≥1 HPV, Female |
78.5% |
73.4% |
74.4% |
82.5% |
||||
|
HPV UTD, Female |
63.8% |
54.8% |
55.7% |
60.9% |
||||
|
≥1 HPV, Male |
75.4% |
69.2% |
85.5% |
72.1% |
||||
|
HPV UTD, Male |
59.8% |
48.3% |
68.7% |
58.4% |
||||
a The same methodology was not used for all years.
View accessible data table of chart below:
Immunization Coverage Estimates for One or More Doses of HPV Coverage Estimates, by Gender, U.S. and Texas, 2012-2021a
|
|
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|---|---|---|---|---|---|---|---|---|---|
|
U.S. Female |
53.8% |
56.7% |
60.0% |
62.8% |
65.1% |
68.6% |
69.9% |
73.2% |
77.1% |
78.5% |
|
Texas, Female |
51.2% |
55.5% |
50.7% |
60.1% |
54.5% |
60.4% |
64.6% |
64.2% |
76.1% |
73.4% |
|
U.S. Male |
20.8% |
33.6% |
41.7% |
49.8% |
56.0% |
62.6% |
66.3% |
69.8% |
73.1% |
75.4% |
|
Texas, Male |
24.0% |
33.7% |
36.6% |
41.4% |
44.3% |
55.2% |
55.5% |
65.9% |
69.6% |
69.2% |
a The same methodology was not used for all years.